Advice
following a full submission
buprenorphine transdermal patches (Butec®) are accepted for restricted use within NHS Scotland.
Indication under review: In adults, for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.
SMC restriction: for use in elderly patients (over 65 years).
Non-inferiority was demonstrated between buprenorphine weekly patches and twice daily oral tramadol in patients with moderate to severe osteoarthritic pain. Non-inferiority was also demonstrated between buprenorphine weekly patches plus oral paracetamol and co-codamol in patients with severe osteoarthritic pain.
Download detailed advice409KB (PDF)
Medicine details
- Medicine name:
- buprenorphine transdermal patch (Butec)
- SMC ID:
- 1213/17
- Indication:
- In adults, for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.
- Pharmaceutical company
- Qdem Pharmaceuticals
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 16 January 2017